SnakeBite911 vs LCAST

*New app! This new SnakeBite911 consolidates an older suite of apps (SnakeBite911ER, SnakeBite911FR and SnakeBite911) into one tool. It features a refreshed design and a new emergency mode for quick access to core functionality.* This useful guide can help educate you about North American venomous pit viper snakes (including rattlesnakes, copperheads and cottonmouths), how to best avoid them, and what to do and what NOT to do should a snake strike happen! This app also works without signal. Features • Emergency support for snakebite emergencies • Quick dial 911 • List of actions you should/shouldn’t take in supporting the snakebite victim • Venom Tracker photo tool to log the spread of venom, which can help save diagnostic and treatment time when the victim gets to the ER • Learn about North American venomous snakes and how to identify them • Learn how to keep safe from snakes and avoid being bitten The new SnakeBite911 app comes from the manufacturers of CroFab® CrotalidaePolyvalent Immune Fab (Ovine), a sheep-derived antivenin indicated for the management of adult and pediatric patients with North American crotalid envenomation. The term crotalid is used to describe the Crotalinae subfamily (formerly known as Crotalidae) of venomous snakes which includes rattlesnakes, copperheads and cottonmouths/water moccasins. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS Do not administer CroFab® to patients with a known hypersensitivity to any of its components, or to papaya or papain unless the benefits outweigh the risks and appropriate management for anaphylactic reactions is readily available. WARNINGS AND PRECAUTIONS Coagulopathy: In clinical trials, recurrent coagulopathy (the return of a coagulation abnormality after it has been successfully treated with antivenin), characterized by decreased fibrinogen, decreased platelets, and elevated prothrombin time, occurred in approximately half of the patients studied; one patient required re-hospitalization and additional antivenin administration. Recurrent coagulopathy may persist for 1 to 2 weeks or more. Patients who experience coagulopathy due to snakebite should be monitored for recurrent coagulopathy for up to 1 week or longer. During this period, the physician should carefully assess the need for re-treatment with CroFab® and use of any type of anticoagulant or anti-platelet drug. Hypersensitivity Reactions: Severe hypersensitivity reactions may occur with CroFab®. In case of acute hypersensitivity reactions, including anaphylaxis and anaphylactoid reactions, discontinue infusion and institute appropriate emergency treatment. Patients allergic to papain, chymopapain, other papaya extracts, or the pineapple enzyme bromelain may also have an allergic reaction to CroFab®. Follow-up all patients for signs and symptoms of delayed allergic reactions or serum sickness (e.g., rash, fever, myalgia, arthralgia). ADVERSE REACTIONS The most common adverse reactions (incidence ≥ 5% of subjects) reported in the clinical studies were urticaria, rash, nausea, pruritus and back pain. Adverse reactions involving the skin and appendages (primarily rash, urticaria, and pruritus) were reported in 12 of the 42 patients. Two patients had a severe allergic reaction (severe hives and a severe rash and pruritus) following treatment and one patient discontinued CroFab® due to an allergic reaction. Recurrent coagulopathy due to envenomation and requiring additional treatment may occur. Find out more at www.CroFab.com, which includes the full Prescribing Information. To report suspected adverse reactions, contact 1-877-377-3784 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

The Lurie Children’s Child Injury Plausibility Assessment Support Tool (LCAST) is an app based on a validated Bruising Clinical Decision Rule (BCDR) called the TEN-4-FACESp. Use of this tool has the potential to improve recognition of abuse in young children with bruising. This app functions only as a screening tool and cannot be used to diagnose abuse. The app applies to children less than 4.0 years of age with bruising. If the child is older than 4.0 and/or bruising is not present, this tool cannot be used. In those circumstances, alternative methods of screening for abuse are needed. WHY FOCUS ON BRUISING? Bruising is the most common injury resulting from physical abuse and is the most overlooked or misdiagnosed antecedent injury prior to an abuse-related fatality or near-fatality in a young child. Bruising occurs from both accidental and abusive trauma, but differences identified by the TEN-4-FACESp bruising clinical decision rule may allow improved and earlier recognition of the abused child. ABOUT THE APP: The app is intended for clinical use by licensed healthcare professionals and providers. The app can inform decision-making and be used as an educational tool for learning about bruising characteristics that commonly result from abusive and accidental injury. The core feature of the app is an interactive 3D body model that allows the user to utilize visual cues of the human body to input clinical observations. The result is the opportunity to compare a child’s bruise findings to the published evidence resulting from a NIH-funded multi-center study. The data that drive the app are based on 2,161 patients of which 410 (19%) were classified by a multi-disciplinary panel of medical experts as abuse and 1,713 (79%) as accident. The TEN-4-FACESp bruising clinical decision rule resulted from analysis of 35 body regions and is 96% specific and 87% sensitive for distinguishing bruising from abuse versus accident. The TEN-4-FACESp has three components based on: 1) specific body regions with bruising, 2) patterned bruising, and 3) bruising anywhere on non-mobile infants. An affirmative finding for any one of the three TEN-4-FACESp components without a clear and reasonable explanation indicates a potential risk for abuse. The child may warrant further evaluation and consultation with an expert in child abuse should be considered. In addition to using the data in this app, the user should always check with a doctor before making any medical decisions.